|
|
 |
|
Viewing report
|
|
|
|
The Future of RNAi Therapeutics: Drug Pipelines and Prospects
Business Insights, Sep 2008, Pages: 253
'The total RNAi therapy market is estimated to value $580m by 2012. This forecast is based upon current treatments, levels of market satisfaction and five new Phase II/III RNAi agents profiled in this report.'
RNA interference continues to offer significant promise for a host of therapeutic treatments. Potentially any disease-causing gene, cell type or tissue can be targeted with RNAi, including those not ‘druggable’ with small molecules or protein-based therapies. Pharma companies are increasingly investing in siRNA optimization or examining siRNA alternatives, in addition to staking out proprietary positions in lipid-based, nanotransporter-based and alternative delivery technologies. The development and licensing of such platforms will become crucial for developers over the coming years.
‘The Future of RNAi Therapeutics: Drug pipelines and prospects’ is a report published by Business Insights that provides an in-depth assessment of recent progress and future opportunities for RNAi players in major therapeutic areas including infectious diseases, cancer, inflammation/immune dysfunction, CNS disorders and cardiology/metabolism.
The latest trends in RNAi therapeutics are examined, focusing on the main areas of clinical need, general/proprietary technologies and company pipelines, and the activities and strategies of 37 RNAi-based developers are profiled. This report also provides forecasts for market growth to 2012 across major RNAi market segments. Identify the developmental status of key RNAi agents, review the latest advances in RNAi technologies and assess the competitive landscape with this report’s analysis of 37 companies across major therapeutic areas.
Measure the developmental progress of 97 RNAi agents, review the latest advances in delivery technologies and evaluate 37 RNAi-based companies across major therapeutic areas...
Use this report to...
- Analyze emerging RNAi agents and delivery technologies and examine new molecular targets and pipeline antisense drugs.
- Evaluate 97 RNAi compounds in development for infectious and inflammatory diseases, cancer and other major disease categories.
- Assess 37 competitors and potential collaborators developing RNAi technologies and examine the latest RNAi-related patenting trends.
- Identify potential growth segments and develop future strategies with this report’s forecasts for the global RNAi therapy market to 2012.
Key findings...
- The total RNAi therapy market is forecast to reach a value of $580mn by 2012. This forecast is based upon current treatments, levels of market satisfaction and five new Phase II/III RNAi agents identified by Business Insights which are targeted at wet age-related macular degeneration, RSV infection and acute renal failure.
- Human proof-of-concept has been produced in a Phase 2 trial of an inhaled siRNA targeting respiratory syncytial virus (RSV). The trial returned a lower RSV infection rate, a greater number of subjects remaining infection-free and was well tolerated. At least 18 other anti-viral RNAi therapeutics are in commercial development.
- Therapeutic RNAi is being applied in cancer to target genes expressed during tumor development. There are 29 RNAi therapeutic cancer products currently in commercial development.
- At least 22 RNAi therapeutic products are in development for conditions involving pathological inflammation. The most advanced programs are in wet age-related macular degeneration.
- Sirna Therapeutics are the most prolific innovator in the field according to a Business Insights proprietary survey of over 2,000 RNAi-related patents and applications. Infectious diseases and cancer were found to be the main therapeutic applications claimed.
Product samples
A sample for this product is available. Please Login/Register to download this sample.
Customers who bought this item also bought
RNAi - Technologies, Markets and Companies
Outlook for RNAi, 2007: siRNA and miRNA in Biology, Diagnostics and Therapeutics
RNAi 2008
Delivering RNAi-Based Therapeutics & Diagnostics: Challenges & Opportunities
Realizing the Promise of Therapeutic RNAi: Emerging Strategies for RNAi Delivery
RNAi Therapeutics 2008 Market Report
The Outlook For RNAi: Accelerating Drug Discovery and the Development of RNAi Therapeutics
RNAi: Broad Application, Expansive Opportunity, 2nd Edition
Advances in RNAi--A Global Technology Assessment (Technical Insights)
RNAi/MicroRNA Market Report 2007
U.S. RNAi Markets
The Exploding RNAi Market & Future Direction Translating the Genome into a Large Market by 2009
|
|
|
|
